What Is a Blood Infusion and When Do You Need One?

A blood infusion, more commonly called a blood transfusion, is a medical procedure in which donated blood or specific blood components are delivered into your bloodstream through an intravenous (IV) line. You might need one any time your body cannot keep up with blood loss or cannot produce enough healthy blood cells on its own, whether that is during emergency surgery, after a car accident, or over the course of cancer treatment. The procedure is one of the most common in hospitals worldwide, yet most people have only a vague idea of what is actually flowing through the tube, why their doctor ordered it, and what could go wrong.

What Actually Goes Into Your Veins

Most people picture a bag of whole blood hanging from a pole, but modern transfusion medicine almost always breaks donated blood into individual components so you receive only what you need. The main products are packed red blood cells, plasma, platelets, and cryoprecipitate. A single unit of whole blood is roughly equivalent to one unit of red blood cells, one unit of plasma, and a fraction of a unit of platelets.¹ Separating these components means a trauma patient bleeding heavily can get concentrated red cells for oxygen delivery, while a cancer patient whose bone marrow has been suppressed might only need platelets.

• Packed red blood cells: the workhorse of transfusion. They carry oxygen from your lungs to every tissue in your body and are the product given most often during surgery or after significant bleeding.
• Plasma: the liquid portion of blood, rich in clotting factors. Trauma teams use it alongside red cells to keep blood from becoming too thin to clot.
• Platelets: tiny cell fragments that plug wounds and start the clotting process. They are the go-to product for patients with dangerously low platelet counts, such as those undergoing chemotherapy.
• Cryoprecipitate: a concentrated preparation derived from plasma that contains high levels of fibrinogen and von Willebrand factor, both critical for clot formation.²

Whole blood transfusions have not disappeared entirely. Military medicine and some civilian trauma centers have revived interest in whole blood for patients in hemorrhagic shock, because giving everything at once can simplify rapid resuscitation.

How a Transfusion Helps Your Body

The most immediate benefit of a red blood cell transfusion is restoring your blood’s ability to carry oxygen. When you lose a large volume of blood, two things happen at once: your oxygen-carrying capacity drops because you have fewer red cells, and your blood becomes thinner, which disrupts how it flows through tiny capillaries. Transfused red cells address both problems simultaneously, restoring viscosity and oxygen-carrying capacity so that the smallest blood vessels can resume normal perfusion.³ Studies measuring tissue oxygenation with near-infrared sensors have confirmed that transfusions increase the number of functioning capillaries and improve oxygen delivery at the tissue level.⁴

That said, a transfusion is not a magic refill. Stored red cells undergo gradual changes over their shelf life that can reduce their flexibility and oxygen-releasing ability. Clinicians weigh the freshness of available blood, the patient’s hemoglobin level, and whether the patient is actively bleeding before deciding how many units to give. The goal is to transfuse enough to get out of danger but not so much that you pile on unnecessary risks.

When Transfusions Are Used in Trauma and Surgery

Acute blood loss is the most dramatic reason for a transfusion. A car crash, a gunshot wound, or a ruptured blood vessel can empty a substantial portion of your blood volume in minutes, and no drug can replace what is lost quickly enough. Trauma teams typically reach for red blood cells when a patient’s hemoglobin drops below a critical threshold, though the exact trigger varies by hospital protocol and patient age. In elderly trauma patients, the margin is narrower: research on trauma transfusion volumes shows that the volume of red cells associated with a fifty-percent predicted mortality is dramatically lower in patients aged eighty and older compared to the general trauma population.⁵

Major elective surgeries, such as hip replacements, cardiac bypasses, and liver transplants, can also involve significant blood loss. Surgeons and anesthesiologists plan ahead by ensuring compatible blood is available and sometimes by using strategies to minimize donor blood use, which we will cover later.

Neurosurgery is an area where transfusion strategy gets particularly nuanced. A study of patients undergoing craniotomy for traumatic brain injury compared a restrictive strategy, transfusing only when hemoglobin dropped below roughly 8 g/dL, against a more liberal approach that transfused at 9 g/dL.⁶ The balance between keeping the brain well oxygenated and avoiding the downsides of extra transfused blood is still debated, but the trend in most surgical specialties has shifted toward giving less blood rather than more, unless the patient is clearly deteriorating.

Chronic Conditions That Require Ongoing Transfusions

Not every transfusion is a one-time emergency event. People with inherited blood disorders like thalassemia or sickle cell disease may need regular transfusions throughout their lives to maintain safe hemoglobin levels and prevent organ damage.⁷ These patients typically visit a transfusion center every few weeks, and managing iron overload from all that extra blood becomes a parallel medical challenge requiring its own medication regimen.

Kidney disease is another common driver. Healthy kidneys produce erythropoietin, a hormone that tells your bone marrow to make red blood cells. When the kidneys fail, that signal weakens and anemia develops. While synthetic erythropoietin injections can help, some patients still require periodic transfusions to bridge the gap.

Bone marrow failure conditions, including aplastic anemia and myelodysplastic syndromes, represent yet another category. The marrow itself is unable to produce enough cells, so transfusions of red cells and platelets keep patients stable while they await treatment or a bone marrow transplant.

Platelet Transfusions in Cancer Care

Chemotherapy is famously hard on the bone marrow. When a patient’s platelet count plummets after treatment, the risk of serious bleeding rises sharply. Guidelines from hematology societies generally recommend a prophylactic platelet transfusion when the count falls below about 10,000 per microliter during the deepest dip, known as the nadir, after a chemotherapy cycle.⁸ If the patient needs a surgical procedure, the threshold rises to around 50,000 per microliter.⁹

Platelet transfusions have real limitations, though. The bump in platelet count they provide is temporary and unpredictable, platelet supplies are chronically limited, and some patients develop antibodies that make them resistant to future transfusions.⁸ For these reasons, platelet transfusions are reserved for episodes of active bleeding, necessary invasive procedures, and severe drops in count rather than being given routinely to keep numbers up throughout chemotherapy.

Transfusions for Newborns and Infants

Premature babies in neonatal intensive care units are among the most frequently transfused patients, relative to their size. Their tiny blood volumes mean that even small amounts of blood drawn for lab tests can cause meaningful anemia. Red cell transfusions in this group follow strict hemoglobin thresholds tailored to gestational age and how much breathing support the baby needs.

Platelet transfusions in newborns follow their own guidelines. For a non-bleeding neonate, transfusion is generally recommended when the platelet count drops below 25,000 per microliter, while a bleeding baby may be transfused at counts below 50,000 to 100,000 per microliter depending on the severity.¹⁰ Neonatal transfusion medicine is cautious by nature, because the developing immune system and small blood volume leave little room for error.

How Your Blood Gets Matched

Before a single drop enters your vein, the blood bank runs a series of compatibility checks. The process starts with blood group typing, which identifies the A, B, and D (Rh) antigens on your red cells, and confirms the result by checking for the expected antibodies in your plasma.¹¹ An antibody screen then looks for any unexpected antibodies you may have developed from a prior transfusion, pregnancy, or other immune exposure. Finally, a crossmatch mixes a small amount of your plasma with the donor’s red cells as a last-chance check for a reaction before the unit is released.

Getting the match wrong can be catastrophic. If you are type O and receive type A red cells, your immune system treats those A-antigen cells as foreign invaders. Antibodies in your plasma latch onto the transfused cells and activate the complement system, a cascade that punches holes in the red cell membranes and destroys them. The resulting hemolytic reaction can trigger kidney failure, shock, and death.¹² This is why every hospital has strict protocols requiring two independent checks of patient identity before hanging a bag of blood.

What Happens During the Procedure

The actual transfusion is straightforward from the patient’s perspective. A nurse places or accesses an IV line, connects the blood bag through a special administration set fitted with a filter (pore size typically between 170 and 260 microns) designed to catch clots and cellular debris, and starts the infusion slowly.¹³ The first fifteen minutes are monitored closely because most severe reactions announce themselves early. Vital signs are checked at set intervals throughout. A single unit of red cells typically takes one to two hours to infuse, though the rate can be pushed faster in an emergency.

Risks and Complications

Transfusions are far safer than they were a generation ago, but they are not risk-free. The complications fall into a few broad categories.

Febrile and Allergic Reactions

The most common adverse event is a febrile non-hemolytic transfusion reaction, which causes fever and chills during or shortly after the infusion. This can be triggered by antibodies against white blood cell antigens or by inflammatory molecules that accumulate in stored blood products. When it happens, the transfusion is paused, the patient’s identity and blood type are rechecked, and hemolysis and other serious causes are ruled out before treatment with antipyretic medication.¹⁴ Mild allergic reactions, usually hives and itching, are also relatively common and typically respond to antihistamines.

Lung-Related Complications

Two more serious conditions involve the lungs. Transfusion-related acute lung injury (TRALI) is a sudden onset of breathing difficulty, low blood pressure, and fever that usually appears within the first one to six hours after a transfusion.¹⁵ It is thought to involve immune-mediated damage to the lung’s blood vessels and, while uncommon, can be life-threatening. The hallmark symptoms are rapid breathing, low oxygen levels, frothy sputum, and sometimes a sharp drop in blood pressure.¹⁶

Transfusion-associated circulatory overload (TACO) looks similar on the surface but has a different cause: the patient’s heart simply cannot handle the extra fluid volume. Patients already at risk for heart failure are especially vulnerable. A case-control study found that chronic use of loop diuretics, hemorrhagic shock, body weight under 46 kg, and chronic high blood pressure were all independently associated with TACO.¹⁷ Distinguishing TACO from TRALI at the bedside can be difficult; even specialized blood biomarkers cannot reliably separate the two.¹⁸

Infection Risk

The risk of catching an infection from a transfusion has plummeted over the past few decades thanks to rigorous donor screening. Modern blood banks test every donation for HIV, hepatitis B, hepatitis C, and other pathogens using both antibody-based methods and nucleic acid testing (NAT), which can detect viral genetic material before antibodies develop. One large-center study comparing two NAT platforms found that nucleic acid testing caught additional hepatitis B infections that standard antibody screening missed.¹⁹ While no screening system is perfect, the residual risk of viral transmission from a screened unit is now extremely low in countries with modern blood banking infrastructure.

Alternatives to Donor Blood

Because transfusions carry real risks and donor blood is a limited resource, clinicians use several strategies to reduce or avoid them when possible.

Cell salvage, sometimes called intraoperative blood recovery, collects blood lost during surgery, washes it, and returns the patient’s own red cells back into their bloodstream. Guidelines recommend cell salvage whenever it can reasonably be expected to reduce the need for donor blood or prevent severe postoperative anemia.²⁰ Modeling studies have suggested that intraoperative salvage often allows patients to tolerate greater surgical blood loss than preoperative autologous donation, where you bank your own blood weeks before surgery.²¹

Drug-based approaches can also help. Erythropoietin, the synthetic version of the kidney hormone that drives red cell production, can be paired with intravenous iron to boost hemoglobin before or after surgery, reducing the odds of needing a donor transfusion.²² Tranexamic acid, a drug that slows the breakdown of blood clots, is now routinely used in trauma and surgical settings to cut down on bleeding in the first place.

When Patients Refuse Transfusions

Jehovah’s Witnesses decline transfusions of blood and blood products on religious grounds, a position that poses real challenges when major blood loss occurs.²³ Hospitals that regularly care for these patients have developed “bloodless medicine” programs that lean heavily on the alternatives described above, including aggressive use of erythropoietin, iron supplementation, cell salvage, and careful surgical technique to minimize blood loss. These programs have pushed the boundaries of what is possible without donor blood. A case report of a Jehovah’s Witness patient who survived a ruptured abdominal aortic aneurysm repair using a purely bloodless, multidisciplinary approach illustrates how far these strategies have come.²⁴ The techniques developed for this population have filtered into mainstream practice, benefiting all patients by reducing unnecessary transfusions.

The Search for Artificial Blood

The idea of a shelf-stable, universally compatible blood substitute has been pursued for decades. The most promising approach involves hemoglobin-based oxygen carriers (HBOCs), which use various forms of hemoglobin outside of red blood cells to deliver oxygen to tissues.²⁵ These products could theoretically be used in emergencies, on battlefields, or in remote areas where refrigerated donor blood is unavailable.

Despite decades of research, no blood substitute has received full FDA approval for routine clinical use. Early-generation HBOCs caused problems like dangerously high blood pressure and organ damage. Newer formulations have shown more promise, and at least one has been granted “orphan drug” status by the FDA, a designation that encourages development for rare conditions where existing treatments are inadequate.²⁶ The goal remains tantalizing but elusive: a product that carries oxygen reliably, works in any patient regardless of blood type, and can sit on a shelf at room temperature without degrading.

A Surprisingly Recent History

Blood transfusion feels like it has been around forever, but safe human-to-human transfusion is barely a century old. The very first transfusions in humans were actually cross-species experiments. In 1667, Jean-Baptiste Denis transfused lamb’s blood into a human patient, and Richard Lower did the same to a clergyman named Arthur Coga in England that same year.²⁷ When one of Denis’s patients died, the practice was banned in France in 1670, and transfusion largely disappeared from medical practice for the next two centuries.²⁸

It was Karl Landsteiner’s discovery of the ABO blood groups in 1900 that made safe transfusion possible. Once doctors understood that mixing incompatible blood types caused fatal reactions, they could match donors to recipients. Cross-matching techniques improved through the early twentieth century, blood banking emerged during World War II, and the system of component therapy we use today gradually took shape. The entire infrastructure of modern transfusion medicine, from volunteer donor registries to nucleic acid screening, rests on that foundational insight that not all blood is interchangeable.